C. Chabannon, J. Kuball, E. Mcgrath, P. Bader, C. Dufour et al., CAR-T cells: the narrow path between hope and bankruptcy?, Bone Marrow Transplantation, vol.52, issue.12, pp.1588-1597, 2017.
DOI : 10.14694/EDBK_174893
URL : https://www.nature.com/articles/bmt2017241.pdf

C. Grunder, S. Van-dorp, S. Hol, E. Drent, T. Straetemans et al., ??9 and ??2CDR3 domains regulate functional avidity of T cells harboring ??9??2TCRs, Blood, vol.120, issue.26, pp.5153-62, 2012.
DOI : 10.1182/blood-2012-05-432427
URL : http://www.bloodjournal.org/content/bloodjournal/120/26/5153.full.pdf

Z. Sebestyen, W. Scheper, A. Vyborova, S. Gu, Z. Rychnavska et al., RhoB Mediates Phosphoantigen Recognition by V??9V??2??T Cell Receptor, Cell Reports, vol.15, issue.9, pp.1973-85, 2016.
DOI : 10.1016/j.celrep.2016.04.081
URL : https://doi.org/10.1016/j.celrep.2016.04.081

S. Gu, J. Sachleben, C. Boughter, W. Nawrocka, M. Borowska et al., Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on V??9V??2 T cell activation, Proceedings of the National Academy of Sciences, vol.15, issue.35, pp.7311-7331, 2017.
DOI : 10.1016/0021-9991(77)90098-5
URL : http://europepmc.org/articles/pmc5584448?pdf=render

V. Marcu-malina, S. Heijhuurs, M. Van-buuren, L. Hartkamp, S. Strand et al., Redirecting ????T cells against cancer cells by transfer of a broadly tumor-reactive ????T-cell receptor, Blood, vol.118, issue.1, pp.50-59, 2011.
DOI : 10.1182/blood-2010-12-325993
URL : http://www.bloodjournal.org/content/bloodjournal/118/1/50.full.pdf

W. Scheper, C. Grunder, and J. Kuball, Multifunctional gammadelta T cells and their receptors for targeted anticancer immunotherapy, Oncoimmunology, vol.2, issue.5, 2013.
DOI : 10.4161/onci.23974
URL : http://www.tandfonline.com/doi/pdf/10.4161/onci.23974?needAccess=true

W. Scheper, C. Grunder, T. Straetemans, Z. Sebestyen, and J. Kuball, Hunting for clinical translation with innate-like immune cells and their receptors, Leukemia, vol.21, issue.6, pp.1181-90, 2014.
DOI : 10.1016/j.coi.2009.02.009

T. Straetemans, C. Grunder, S. Heijhuurs, S. Hol, I. Slaper-cortenbach et al., Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer, Clinical Cancer Research, vol.21, issue.17, pp.3957-68, 2015.
DOI : 10.1158/1078-0432.CCR-14-2860

M. Braham, M. Minnema, T. Aarts, Z. Sebestyen, T. Straetemans et al., Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model, OncoImmunology, vol.2, issue.6, 2018.
DOI : 10.1038/ni1001-962

K. Ghani, S. Cottin, A. Kamen, and M. Caruso, Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media, Gene Therapy, vol.96, issue.24, pp.1705-1716, 2007.
DOI : 10.1089/10430340252899046

K. Ghani, X. Wang, P. De-campos-lima, M. Olszewska, A. Kamen et al., Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-Pseudotyped Retroviral Vectors Produced in Suspension and Serum-Free Media, Human Gene Therapy, vol.20, issue.9, pp.966-74, 2009.
DOI : 10.1089/hum.2009.001

B. Levine, W. Bernstein, M. Connors, N. Craighead, T. Lindsten et al., Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells, J Immunol, issue.12, pp.1595921-1595951, 1997.

R. Brentjens, I. Riviere, J. Park, M. Davila, X. Wang et al., Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, vol.118, issue.18, pp.4817-4845, 2011.
DOI : 10.1182/blood-2011-04-348540

R. Gomez-eerland, B. Nuijen, B. Heemskerk, N. Van-rooij, J. Van-den-berg et al., Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype, Human Gene Therapy Methods, vol.25, issue.5, pp.277-87, 2014.
DOI : 10.1089/hgtb.2014.004

M. Kalos, B. Levine, D. Porter, S. Katz, S. Grupp et al., T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia, Science Translational Medicine, vol.102, issue.6, 2011.
DOI : 10.1182/blood-2003-01-0095

D. Porter, B. Levine, M. Kalos, A. Bagg, and C. June, Chimeric Antigen Receptor???Modified T Cells in Chronic Lymphoid Leukemia, New England Journal of Medicine, vol.365, issue.8, pp.725-758, 2011.
DOI : 10.1056/NEJMoa1103849

B. Levine, J. Miskin, K. Wonnacott, and C. Keir, Global Manufacturing of CAR T Cell Therapy, Molecular Therapy - Methods & Clinical Development, vol.4, pp.92-101, 2017.
DOI : 10.1016/j.omtm.2016.12.006

C. Lamers, R. Willemsen, B. Luider, R. Debets, and R. Bolhuis, Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer, Cancer Gene Therapy, vol.166, issue.7, pp.613-636, 2002.
DOI : 10.1016/S0022-5347(05)66149-6

R. Voss, J. Kuball, and T. M. , Designing TCR for Cancer Immunotherapy, Methods Mol Med, vol.109, pp.229-56229, 2005.
DOI : 10.1385/1-59259-862-5:229

J. Gaschet, A. Lim, L. Liem, R. Vivien, M. Hallet et al., Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch., Journal of Clinical Investigation, vol.98, issue.1, pp.100-107, 1996.
DOI : 10.1172/JCI118753

C. Klebanoff, L. Gattinoni, and N. Restifo, CD8+ T-cell memory in tumor immunology and immunotherapy, Immunological Reviews, vol.61, issue.1, pp.214-238, 2006.
DOI : 10.1016/j.coi.2005.02.002

D. Sommermeyer, M. Hudecek, P. Kosasih, T. Gogishvili, D. Maloney et al., Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo, Leukemia, vol.90, issue.2, pp.492-500, 2016.
DOI : 10.1038/nm.1982

D. Macleod, A. J. Martin, A. Moser, R. Hekele, A. Wetzel et al., Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells, Molecular Therapy, vol.25, issue.4, pp.949-61, 2017.
DOI : 10.1016/j.ymthe.2017.02.005

M. Legut, G. Dolton, A. Mian, O. Ottmann, and A. Sewell, CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells, Blood, vol.131, issue.3, pp.311-333, 2018.
DOI : 10.1182/blood-2017-05-787598

D. Lock, N. Mockel-tenbrinck, K. Drechsel, C. Barth, D. Mauer et al., Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use, Human Gene Therapy, vol.28, issue.10, pp.914-939, 2017.
DOI : 10.1089/hum.2017.111

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466

M. Smith, J. Zakrzewski, S. James, and M. Sadelain, Posttransplant chimeric antigen receptor therapy, Blood, vol.131, issue.10, pp.1045-52, 2018.
DOI : 10.1182/blood-2017-08-752121

J. Abad, C. Wrzensinski, W. Overwijk, D. Witte, M. Jorritsma et al., T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model, Journal of Immunotherapy, vol.31, issue.1, pp.1-6, 2008.
DOI : 10.1097/CJI.0b013e31815c193f

M. De-witte, A. Jorritsma, A. Kaiser, M. Van-den-boom, M. Dokter et al., Requirements for Effective Antitumor Responses of TCR Transduced T Cells, The Journal of Immunology, vol.181, issue.7, pp.5128-5164, 2008.
DOI : 10.4049/jimmunol.181.7.5128

R. Gardner, O. Finney, C. Annesley, H. Brakke, C. Summers et al., Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, vol.129, issue.25, pp.3322-3353, 2017.

C. Traversari, S. Marktel, Z. Magnani, P. Mangia, V. Russo et al., The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies, Blood, vol.109, issue.11, pp.4708-4723, 2006.
DOI : 10.1182/blood-2006-04-015230

A. Neurauter, M. Bonyhadi, L. E. Nokleby, L. Ruud, E. Camacho et al., Cell Isolation and Expansion Using Dynabeads ??, Adv Biochem Eng Biotechnol, vol.106, pp.41-73, 2007.
DOI : 10.1007/10_2007_072

, 3(s). (2017) Available from: https://www.gpo.gov/fdsys, FDA. 21 CFR, 2018.

, Available from: https://www.fda. gov, UCM566166.pdf (Accessed, 2017.

Q. Xue, E. Bettini, P. Paczkowski, C. Ng, A. Kaiser et al., Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response, Journal for ImmunoTherapy of Cancer, vol.3, issue.1, pp.85-95, 2017.
DOI : 10.1158/2326-6066.CIR-14-0195